Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic
Patient-derived xenograft (PDX) models are created by implanting fresh human tumor tissue directly into immunocompromised mice, as opposed to cell line-derived xenograft (CDX) models, which originate from established human cancer cell lines that have been passaged in culture for many generations before being implanted into mice. PDX models allow for tumors to grow in a microenvironment that more closely mimics the human tumor microenvironment, including the presence of stromal cells and extracellular matrix components.
While both forms of xenograft models utilize human cells in immunocompromised mice, PDX models are considered more clinically relevant than CDX models because they preserve the heterogeneity and genetic complexity of the original tumor and can better predict patient response to treatment. While CDX models are easier and faster to create than PDX models, they do not capture the full complexity of the tumor microenvironment, and their responses to treatment may not accurately reflect what is seen in patients. PDX models contain all of the genetic and epigenetic changes that were present in the patient’s tumor, while CDX models only contain the genetic changes that were present in the cancer cell line. In addition, PDX models are more heterogeneous than CDX models because contain a variety of different cell types, while CDX models are typically composed of a single cell type. As a result, PDX models response to a given treatment may more faithfully recapitulate the response of the patient’s original tumor.
While PDX models may be run in immunocompromised animals and therefore are not suitable for studying immune therapies such as CAR-T or checkpoint inhibitors (exception being humanized mouse host), their faithful recapitulation of the human tumor microenvironment and genetic heterogeneity make them particularly well-suited for evaluating targeted therapies such as monoclonal antibodies or combination therapies.
If you have access to clinical samples from which you want to initiate a PDX study Melior is able to, with short lead times, and flexibility for bespoke study designs, accommodate most client needs.
1. Hidalgo, M., Amant, F., Biankin, A. V., Budinska, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Maelandsmo, G. M., Roman-Roman, S., Seoane, J., Trusolino, L., Villanueva, A., Patient-derived xenograft models: an emerging platform for translational cancer research, Cancer Discov. 2014, 4(9):998-1013. doi: 10.1158/2159-8290.CD-14-0001.
2. Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., Eckhardt, S. G., Patient-derived tumour xenografts as models for oncology drug development, Nat. Rev. Clin. Oncol. 2012, 9(6):338-350. doi: 10.1038/nrclinonc.2012.61.
3. Rubio-Viqueira, B., Hidalgo, M., Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients, Clin. Pharmacol. Ther. 2009, 85(2):217-221. doi: 10.1038/clpt.2008.213.
4. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., Potmesil, M., DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts, Science 1989, 246(4933):1046-1048. doi: 10.1126/science.2556796.